ERBB2 and neoplasm: The reduction of tumor cell survival by the EDC-Herceptin conjugate was Her2-expression specific because no reduction of cell viability was observed in the two independent Her2-underexpressing cell lines, MDA-MB-468 [17] and Col (Figures 2a and b).